Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)

Autor: Hee Kyung Ahn, Eun Joo Kang, Seong Hoon Shin, Sung-Bae Kim, Y. Lee, Keon Uk Park, Jung Hye Kwon, Kyoung Eun Lee, Keun Wook Lee, Hwan Jung Yun, Hye Ryun Kim, Min Kyoung Kim, Jin-Soo Kim, Jin-Hyuk Choi, Bhumsuk Keam
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Male
Cancer Research
medicine.medical_treatment
Cetuximab
Docetaxel
0302 clinical medicine
Antineoplastic Agents
Immunological
Squamous cell carcinoma
Antineoplastic Combined Chemotherapy Protocols
Locally advanced head and neck cancer
Aged
80 and over
Chemoradiotherapy
Induction Chemotherapy
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Combined Modality Therapy
Progression-Free Survival
Survival Rate
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Female
Fluorouracil
medicine.drug
Research Article
Adult
medicine.medical_specialty
Antimetabolites
Antineoplastic
Strategy
lcsh:RC254-282
03 medical and health sciences
Young Adult
Internal medicine
Genetics
medicine
Humans
Aged
Retrospective Studies
business.industry
Squamous Cell Carcinoma of Head and Neck
Induction chemotherapy
Retrospective cohort study
Multidisciplinary treatment
medicine.disease
Head and neck squamous-cell carcinoma
Radiation therapy
Regimen
030104 developmental biology
Nasopharyngeal carcinoma
Cisplatin
business
Follow-Up Studies
Zdroj: BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer
ISSN: 1471-2407
Popis: Background By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice. Methods This is a multi-institutional study enrolled the patients with stage III to IVB LA-HNSCC, except for nasopharyngeal carcinoma, from 2004 to 2015 in thirteen referral hospitals capable of multidisciplinary care. Results A total of 445 LA-HNSCC patients were analyzed. The median age was 61 years (range, 24–89). The primary tumor location was the oropharynx in 191 (43%), oral cavity in 106 (24%), hypopharynx in 64 (14%), larynx in 57 (13%) and other sites in 27 (6%). The most common stage was T2 in 172 (39%), and N2 in 245 (55%). Based on treatment intents, 229 (52%) of the patients received definitive concurrent chemoradiotherapy (CCRT) and 187 (42%) underwent surgery. Approximately 158 (36%) of the study population received induction chemotherapy (IC). Taken together, 385 (87%) of the patients underwent combined therapeutic modalities. The regimen for definitive CCRT was weekly cisplatin in 58%, 3-weekly cisplatin in 28% and cetuximab in 3%. The preferred regimen for IC was docetaxel with cisplatin in 49%, and docetaxel, cisplatin plus fluorouracil in 27%. With a median follow-up of 39 months, one-year and two-year survival rates were 89 and 80%, respectively. Overall survival was not significantly different between CCRT and surgery group (p = 0.620). Conclusions In patients with LA-HNSCC, the majority of patients received combined therapeutic modalities. Definitive CCRT, IC then definitive CCRT, and surgery followed by adjuvant CCRT or radiotherapy are the preferred multidisciplinary strategies in real-world practice.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje